search
Back to results

Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder (ASPIRE)

Primary Purpose

Psychotic Disorders, Acceptance and Commitment Therapy, Psychotherapy, Group

Status
Not yet recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
ACT group therapy
Sponsored by
Vivantes Netzwerk für Gesundheit GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Psychotic Disorders focused on measuring Mindfulness, Acceptance and Commitment Therapy, Psychotherapy, Group, Inpatients, Psychotic Disorders

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with psychosis spectrum disorder with the following diagnoses according to the Diagnostic and Statistical Manual Diploma in Social Medicine 5 ("Schizophrenia Spectrum and Other Psychotic Disorders"): Schizophrenia Schizophreniform disorder Schizoaffective disorder Delusional disorder Brief psychotic disorder Psychotic disorder due to another disorder Substance-induced/medication-induced psychotic disorder Depressive episode with psychotic symptoms Manic or bipolar episode with psychotic symptoms Exclusion Criteria: Patients decline to participate in the treatment program Language or intellectual abilities insufficient for study participation

Sites / Locations

  • Vivantes Klinikum Am Urban

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ACT group therapy

Arm Description

High-frequency inpatient ACT group therapy program for patients with psychosis spectrum disorder.

Outcomes

Primary Outcome Measures

Positive and Negative Syndrome Scale (PANSS)
The primary endpoint symptom severity is assessed using the German version of the established Positive and Negative Syndrome Scale (PANSS). The PANSS consists of a third-party assessment interview in which 30 symptoms are rated using a seven-point scale ranging from 1 (nonexistent) to 7 (extreme symptom). Symptoms are assigned to three scales: The Positive Scale, the Negative Scale, and the General Psychopathology Scale. The PANSS is widely used and is considered the gold standard for assessing psychopathology in people with psychotic disorders because of its good reliability and validity.

Secondary Outcome Measures

Global Assessment of Functioning (GAF)
The general level of functioning is assessed using the German version of the Global Assessment of Functioning (GAF) numerical external assessment scale. The GAF is divided into 10 levels of functioning with 10 points each and ranges from 100 (highest level of functioning) to 1 (lowest level of functioning). Environmental conditions and physical illness are explicitly not to be considered here. Mental, social, and occupational functioning are thought of as being on a hypothetical continuum from mental health to illness.
World Health Organization Quality of Life Brief Version (WHOQOL-BREF)
Quality of life is measured with the German version of the WHOQOL-BREF (World Health Organization Quality of Life Brief Version), an abbreviated version of the WHOQOL-100 (World Health Organization Quality of Life 100). The WHOQOL-BREF, which is a brief self-report instrument, consists of a total of 26 items, which are assigned to the 4 domains of physical health (7 items), psychological health (6 items), social relationships (3 items) and environmental health (8 items). Two other items measure overall quality of life and general health. Each individual item of the WHOQOL-BREF is scored from 1 to 5 on a response scale, which is stipulated as a five-point ordinal scale (low score of 1 to high score of 5). The average score for each domain is calculated, resulting in an average domain score between 4 and 20. This average domain score is multiplied by 4 to transform it into a scaled score, with a higher score indicating a better quality of life.
Fragebogen für Akzeptanz und Handeln (FAH-II)
German version of the Acceptance and Action Questionnaire (AAQ-II). The AAQ-II was developed to measure experience avoidance based on the model of psychological flexibility. It consists of a 7-point Likert scale. Participants rated between 1 (never true) and 7 (always true) how well the statements describe them. The range of scores is between 7 and 49. Higher scores on the scale indicate higher experience avoidance and lower psychological flexibility.
Fragebogen zur Messung der Patientenzufriedenheit (ZUF-8)
Patient satisfaction at the end of the intervention is assessed using the German version of the self-report scale Client Satisfaction Questionnaire CSQ-8, the ZUF-8 (Questionnaire for the Measurement of Patient Satisfaction). The eight items are formulated as questions and each have four response options, for which 1-4 points are assigned. After reversal of polarity, all eight item values are summed up to the scale value ZUF-8 (theoretical scale range from 8 to 32). High scale values indicate a high level of "satisfaction", low scale values indicate a low level of "satisfaction".
Questionnaire about the Process of Recovery (QPR)
The German version of the self-report scale Questionnaire about the Process of Recovery (QPR), the Personal Recovery Questionnaire, serves as an instrument for assessing personal recovery. The QPR comprises 15 items, each of which is rated on a 4-point scale (0 = do not agree at all, 1 = do not agree , 2 = partly agree, 3 = agree, 4 = fully agree ) and has been validated in German.
Comprehensive Inventory of Mindfulness Experiences (CHIME)
Mindfulness skills are assessed with the German self-report scale Comprehensive Inventory of Mindfulness Experiences (CHIME). CHIME is a questionnaire for self-assessment of different aspects of mindfulness. It comprises 37 items that are assigned to eight subscales. Items are scored on a 5-point Likert scale ranging from 1 (never) to 5 (very often). The higher the the arithmetic mean the better the mindfulness skills.
Cognitive Fusion Questionnaire (CFQ-D)
Cognitive fusion is assessed with the German version of the self-report questionnaire Cognitive Fusion Questionnaire (CFQ). The Cognitive Fusion Questionnaire (CFQ) assesses cognitive fusion, or rigidly following self-generated rules. The CFQ is a 7 item self-report instrument with a range of 7-49. Higher scores are indicative of a higher level of cognitive fusion.

Full Information

First Posted
October 5, 2023
Last Updated
October 12, 2023
Sponsor
Vivantes Netzwerk für Gesundheit GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT06086184
Brief Title
Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder
Acronym
ASPIRE
Official Title
Pilot Study to Evaluate the Effectiveness of an Acceptance and Commitment Therapy (ACT)-Based Treatment Approach With Inpatient Group Therapy Interventions for Patients With Psychosis Spectrum Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
February 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vivantes Netzwerk für Gesundheit GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The pilot study that will serve as the basis for the larger project - a multicenter randomized controlled single-blinded trial (RCT) will focus on testing the feasibility and efficacy of an inpatient group ACT treatment program and its effects on symptom severity and patient satisfaction in patients with psychosis spectrum disorder. The ACT-specific treatment program for inpatients with psychosis spectrum disorder is designed to enable patients to deal with their disease in an accepting manner over the long term, to promote self-determined and positive attitudes toward treatment and support options, and thus to reduce rehospitalization rates.
Detailed Description
Inpatient hospitalization is an important time to provide patients with psychosis spectrum disorder with skills to better manage symptoms and improve functioning after discharge. The long-term goal is to reduce the negative consequences of these disorders and to have a lasting positive impact on the course of the disease. Against this background, the aim of a larger-scale future study project is to evaluate a specific ACT-based four-week treatment program providing inpatient group therapy interventions for patients with psychosis spectrum disorder. The ACT-specific treatment program is designed to enable patients to deal with their disease in an accepting manner over the long term, to promote self-determined and positive attitudes toward treatment and support options, and thus to reduce rehospitalization rates. The pilot study will focus on testing the feasibility and efficacy of the inpatient group ACT treatment program and its effects on symptom severity and patient satisfaction in patients with psychosis spectrum disorder. Here, treatment will include a high-frequency four-week inpatient ACT group therapy program with a focus on the core ACT process of mindfulness in addition to standard inpatient treatment. Within the scope of the survey, possible side effects of the intervention will also be recorded and mapped by conducting qualitative individual interviews and documenting serious adverse events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psychotic Disorders, Acceptance and Commitment Therapy, Psychotherapy, Group, Inpatients
Keywords
Mindfulness, Acceptance and Commitment Therapy, Psychotherapy, Group, Inpatients, Psychotic Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ACT group therapy
Arm Type
Experimental
Arm Description
High-frequency inpatient ACT group therapy program for patients with psychosis spectrum disorder.
Intervention Type
Behavioral
Intervention Name(s)
ACT group therapy
Intervention Description
Participation in four sessions of the inpatient "Compass Group" and eight sessions of the inpatient "Here-and-Now Group". This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan.
Primary Outcome Measure Information:
Title
Positive and Negative Syndrome Scale (PANSS)
Description
The primary endpoint symptom severity is assessed using the German version of the established Positive and Negative Syndrome Scale (PANSS). The PANSS consists of a third-party assessment interview in which 30 symptoms are rated using a seven-point scale ranging from 1 (nonexistent) to 7 (extreme symptom). Symptoms are assigned to three scales: The Positive Scale, the Negative Scale, and the General Psychopathology Scale. The PANSS is widely used and is considered the gold standard for assessing psychopathology in people with psychotic disorders because of its good reliability and validity.
Time Frame
T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final examinations: After the end of the four-week intervention (week 5) T2 Follow-up examinations: 6 months after the end of the intervention
Secondary Outcome Measure Information:
Title
Global Assessment of Functioning (GAF)
Description
The general level of functioning is assessed using the German version of the Global Assessment of Functioning (GAF) numerical external assessment scale. The GAF is divided into 10 levels of functioning with 10 points each and ranges from 100 (highest level of functioning) to 1 (lowest level of functioning). Environmental conditions and physical illness are explicitly not to be considered here. Mental, social, and occupational functioning are thought of as being on a hypothetical continuum from mental health to illness.
Time Frame
T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention
Title
World Health Organization Quality of Life Brief Version (WHOQOL-BREF)
Description
Quality of life is measured with the German version of the WHOQOL-BREF (World Health Organization Quality of Life Brief Version), an abbreviated version of the WHOQOL-100 (World Health Organization Quality of Life 100). The WHOQOL-BREF, which is a brief self-report instrument, consists of a total of 26 items, which are assigned to the 4 domains of physical health (7 items), psychological health (6 items), social relationships (3 items) and environmental health (8 items). Two other items measure overall quality of life and general health. Each individual item of the WHOQOL-BREF is scored from 1 to 5 on a response scale, which is stipulated as a five-point ordinal scale (low score of 1 to high score of 5). The average score for each domain is calculated, resulting in an average domain score between 4 and 20. This average domain score is multiplied by 4 to transform it into a scaled score, with a higher score indicating a better quality of life.
Time Frame
T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention
Title
Fragebogen für Akzeptanz und Handeln (FAH-II)
Description
German version of the Acceptance and Action Questionnaire (AAQ-II). The AAQ-II was developed to measure experience avoidance based on the model of psychological flexibility. It consists of a 7-point Likert scale. Participants rated between 1 (never true) and 7 (always true) how well the statements describe them. The range of scores is between 7 and 49. Higher scores on the scale indicate higher experience avoidance and lower psychological flexibility.
Time Frame
T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention
Title
Fragebogen zur Messung der Patientenzufriedenheit (ZUF-8)
Description
Patient satisfaction at the end of the intervention is assessed using the German version of the self-report scale Client Satisfaction Questionnaire CSQ-8, the ZUF-8 (Questionnaire for the Measurement of Patient Satisfaction). The eight items are formulated as questions and each have four response options, for which 1-4 points are assigned. After reversal of polarity, all eight item values are summed up to the scale value ZUF-8 (theoretical scale range from 8 to 32). High scale values indicate a high level of "satisfaction", low scale values indicate a low level of "satisfaction".
Time Frame
T1 Final Examinations: After the end of the four-week intervention (week 5)
Title
Questionnaire about the Process of Recovery (QPR)
Description
The German version of the self-report scale Questionnaire about the Process of Recovery (QPR), the Personal Recovery Questionnaire, serves as an instrument for assessing personal recovery. The QPR comprises 15 items, each of which is rated on a 4-point scale (0 = do not agree at all, 1 = do not agree , 2 = partly agree, 3 = agree, 4 = fully agree ) and has been validated in German.
Time Frame
T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention
Title
Comprehensive Inventory of Mindfulness Experiences (CHIME)
Description
Mindfulness skills are assessed with the German self-report scale Comprehensive Inventory of Mindfulness Experiences (CHIME). CHIME is a questionnaire for self-assessment of different aspects of mindfulness. It comprises 37 items that are assigned to eight subscales. Items are scored on a 5-point Likert scale ranging from 1 (never) to 5 (very often). The higher the the arithmetic mean the better the mindfulness skills.
Time Frame
T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention
Title
Cognitive Fusion Questionnaire (CFQ-D)
Description
Cognitive fusion is assessed with the German version of the self-report questionnaire Cognitive Fusion Questionnaire (CFQ). The Cognitive Fusion Questionnaire (CFQ) assesses cognitive fusion, or rigidly following self-generated rules. The CFQ is a 7 item self-report instrument with a range of 7-49. Higher scores are indicative of a higher level of cognitive fusion.
Time Frame
T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention
Other Pre-specified Outcome Measures:
Title
Number of group therapy sessions attended and drop out rate
Description
To provide evidence on the feasibility and acceptability of the intervention, therapy attendance in the ACT-specific group therapy treatment program (reported as number of group therapy sessions attended) and dropouts from study-related treatment (reported as drop out rate in percent) will be recorded.
Time Frame
Therapy attendance during the four-week intervention will be measured at T1 Final Examinations after the end of the four-week intervention (week 5).
Title
Qualitative semi-structured interview analysis according to Mayring
Description
A focused, semi-structured guided interview will be used to explore research questions related to the desirable and undesirable effects of inpatient ACT-specific group therapy. The key questions are: What have ACT group therapies done for you? Is this effect desired for you? Did you experience any unwanted effects? What did you notice about your symptoms during and after ACT group therapy sessions? The qualitative individual interviews are recorded with a recording device and transcribed by the study staff. The evaluation of the transcribed, semi-structured interviews on the desired and undesirable effects of the intervention is carried out using the qualitative content analysis method according to Mayring. The qualitative content analysis according to Mayring is a structured, qualitative method for the systematic and theory-driven evaluation of text-based data.
Time Frame
T1 Final Examinations: After the end of the four-week intervention (week 5).
Title
WHO Alcohol, Smoking and Substance Involvement Screening Test (WHO ASSIST)
Description
Since substance use can have an influence on the development of the measured data to be assessed, substance use will also be systematically recorded.
Time Frame
T0 Baseline Examinations: Before the start of the intervention at study enrollment T2 Follow-up Examinations: 6 months after the end of the intervention
Title
ACT Fidelity Measure (ACT-FM)
Description
The raters use a German translation of the ACT Fidelity Measure (ACT-FM), which is validated in English and can be used in different therapy contexts.
Time Frame
ACT Fidelity Measure will be evaluated during the four-week intervention.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with psychosis spectrum disorder with the following diagnoses according to the Diagnostic and Statistical Manual Diploma in Social Medicine 5 ("Schizophrenia Spectrum and Other Psychotic Disorders"): Schizophrenia Schizophreniform disorder Schizoaffective disorder Delusional disorder Brief psychotic disorder Psychotic disorder due to another disorder Substance-induced/medication-induced psychotic disorder Depressive episode with psychotic symptoms Manic or bipolar episode with psychotic symptoms Exclusion Criteria: Patients decline to participate in the treatment program Language or intellectual abilities insufficient for study participation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andreas Bechdolf, Prof. Dr.
Phone
+4930130226001
Email
andreas.bechdolf@vivantes.de
First Name & Middle Initial & Last Name or Official Title & Degree
Felicitas Ehlen, Dr.
Phone
+4930130226001
Email
felicitas.ehlen@vivantes.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas Bechdolf, Prof. Dr.
Organizational Affiliation
Senior consultant department of psychiatry Vivantes Klinikum Am Urban and Klinikum im Friedrichshain
Official's Role
Study Director
Facility Information:
Facility Name
Vivantes Klinikum Am Urban
City
Berlin-Kreuzberg
State/Province
Berlin
ZIP/Postal Code
10967
Country
Germany
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Prof. Dr. Bechdolf
First Name & Middle Initial & Last Name & Degree
Felicitas Dr. Ehlen

12. IPD Sharing Statement

Learn more about this trial

Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder

We'll reach out to this number within 24 hrs